Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 1/2018

08.12.2017 | NON-THEMATIC REVIEW

Cancer driver G-protein coupled receptor (GPCR) induced β-catenin nuclear localization: the transcriptional junction

verfasst von: Jeetendra Kumar Nag, Tatyana Rudina, Myriam Maoz, Sorina Grisaru-Granovsky, Beatrice Uziely, Rachel Bar-Shavit

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

G protein-coupled receptors (GPCRs) comprise the main signal-transmitting components in the cell membrane. Over the past several years, biochemical and structural analyses have immensely enhanced our knowledge of GPCR involvement in health and disease states. The present review focuses on GPCRs that are cancer drivers, involved in tumor growth and development. Our aim is to highlight the involvement of stabilized β-catenin molecular machinery with a specific array of GPCRs. We discuss recent advances in understanding the molecular path leading to β-catenin nuclear localization and transcriptional activity and their implications for future cancer therapy research.
Literatur
1.
Bjarnadottir, T. K., Gloriam, D. E., Hellstrand, S. H., Kristiansson, H., Fredriksson, R., & Schioth, H. B. (2006). Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. Genomics, 88(3), 263–273.PubMedCrossRef
2.
Bockaert, J., & Pin, J. P. (1999). Molecular tinkering of G protein-coupled receptors: an evolutionary success. The EMBO Journal, 18(7), 1723–1729.PubMedPubMedCentralCrossRef
3.
Feigin, M. E. (2013). Harnessing the genome for characterization of G-protein coupled receptors in cancer pathogenesis. The FEBS Journal, 280(19), 4729–4738.PubMedPubMedCentralCrossRef
4.
Hollenberg, M. D., Mihara, K., Polley, D., Suen, J. Y., Han, A., Fairlie, D. P., et al. (2014). Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease. British Journal of Pharmacology, 171(5), 1180–1194.PubMedPubMedCentralCrossRef
5.
Kenakin, T. (2012). The potential for selective pharmacological therapies through biased receptor signaling. BMC Pharmacology & Toxicology, 13, 3.CrossRef
6.
Miao, Y., & McCammon, J. A. (2016). G-protein coupled receptors: advances in simulation and drug discovery. Current Opinion in Structural Biology, 41, 83–89.PubMedPubMedCentralCrossRef
7.
Wisler, J. W., Xiao, K., Thomsen, A. R., & Lefkowitz, R. J. (2014). Recent developments in biased agonism. Current Opinion in Cell Biology, 27, 18–24.PubMedCrossRef
8.
Premont, R. T., & Gainetdinov, R. R. (2007). Physiological roles of G protein-coupled receptor kinases and arrestins. Annual Review of Physiology, 69, 511–534.PubMedCrossRef
9.
Clevers, H. (2006). Wnt/beta-catenin signaling in development and disease. Cell, 127(3), 469–480.PubMedCrossRef
10.
Nusse, R. (2005). Wnt signaling in disease and in development. Cell Research, 15(1), 28–32.PubMedCrossRef
11.
Liu, T., DeCostanzo, A. J., Liu, X., Wang, H., Hallagan, S., Moon, R. T., et al. (2001). G protein signaling from activated rat frizzled-1 to the beta-catenin-Lef-Tcf pathway. Science, 292(5522), 1718–1722.PubMedCrossRef
12.
Wang, H. Y., & Malbon, C. C. (2004). Wnt-frizzled signaling to G-protein-coupled effectors. Cellular and Molecular Life Sciences: CMLS, 61(1), 69–75.PubMedCrossRef
13.
14.
Potts, J. T., & Gardella, T. J. (2007). Progress, paradox, and potential: parathyroid hormone research over five decades. Annals of the New York Academy of Sciences, 1117, 196–208.PubMedCrossRef
15.
Honore, P., Luger, N. M., Sabino, M. A., Schwei, M. J., Rogers, S. D., Mach, D. B., et al. (2000). Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nature Medicine, 6(5), 521–528.PubMedCrossRef
16.
Southby, J., Kissin, M. W., Danks, J. A., Hayman, J. A., Moseley, J. M., Henderson, M. A., et al. (1990). Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Research, 50(23), 7710–7716.PubMed
17.
McCauley, L. K., & Martin, T. J. (2012). Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine. Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research, 27(6), 1231–1239.CrossRef
18.
Allison, D. C., Carney, S. C., Ahlmann, E. R., Hendifar, A., Chawla, S., Fedenko, A., et al. (2012). A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma, 2012, 704872.PubMedPubMedCentralCrossRef
19.
Fearon, K., Arends, J., & Baracos, V. (2013). Understanding the mechanisms and treatment options in cancer cachexia. Nature Reviews. Clinical Oncology, 10(2), 90–99.PubMedCrossRef
20.
Fearon, K. C., Glass, D. J., & Guttridge, D. C. (2012). Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metabolism, 16(2), 153–166.PubMedCrossRef
21.
Kir, S., White, J. P., Kleiner, S., Kazak, L., Cohen, P., Baracos, V. E., et al. (2014). Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature, 513(7516), 100–104.PubMedPubMedCentralCrossRef
22.
Ovesen, L., Allingstrup, L., Hannibal, J., Mortensen, E. L., & Hansen, O. P. (1993). Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 11(10), 2043–2049.CrossRef
23.
24.
Barnes, M. R., Duckworth, D. M., & Beeley, L. J. (1998). Frizzled proteins constitute a novel family of G protein-coupled receptors, most closely related to the secretin family. Trends in Pharmacological Sciences, 19(10), 399–400.PubMedCrossRef
25.
Romero, G., Sneddon, W. B., Yang, Y., Wheeler, D., Blair, H. C., & Friedman, P. A. (2010). Parathyroid hormone receptor directly interacts with dishevelled to regulate beta-catenin signaling and osteoclastogenesis. The Journal of Biological Chemistry, 285(19), 14756–14763.PubMedPubMedCentralCrossRef
26.
Boyce, B. F., Xing, L., & Chen, D. (2005). Osteoprotegerin, the bone protector, is a surprising target for beta-catenin signaling. Cell Metabolism, 2(6), 344–345.PubMedPubMedCentralCrossRef
27.
Goldring, S. R., & Goldring, M. B. (2007). Eating bone or adding it: the Wnt pathway decides. Nature Medicine, 13(2), 133–134.PubMedCrossRef
28.
Holmen, S. L., Zylstra, C. R., Mukherjee, A., Sigler, R. E., Faugere, M. C., Bouxsein, M. L., et al. (2005). Essential role of beta-catenin in postnatal bone acquisition. The Journal of Biological Chemistry, 280(22), 21162–21168.PubMedCrossRef
29.
Yao, W., Cheng, Z., Shahnazari, M., Dai, W., Johnson, M. L., & Lane, N. E. (2010). Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research, 25(2), 190–199.CrossRef
30.
Diarra, D., Stolina, M., Polzer, K., Zwerina, J., Ominsky, M. S., Dwyer, D., et al. (2007). Dickkopf-1 is a master regulator of joint remodeling. Nature Medicine, 13(2), 156–163.PubMedCrossRef
31.
Wan, M., Yang, C., Li, J., Wu, X., Yuan, H., Ma, H., et al. (2008). Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes & Development, 22(21), 2968–2979.CrossRef
32.
Torrance, C. J., Jackson, P. E., Montgomery, E., Kinzler, K. W., Vogelstein, B., Wissner, A., et al. (2000). Combinatorial chemoprevention of intestinal neoplasia. Nature Medicine, 6(9), 1024–1028.PubMedCrossRef
33.
34.
Vane, J. R., & Botting, R. M. (1998). Mechanism of action of nonsteroidal anti-inflammatory drugs. The American Journal of Medicine, 104(3A), 2S–8S discussion 21S-22S.PubMedCrossRef
35.
Castellone, M. D., Teramoto, H., Williams, B. O., Druey, K. M., & Gutkind, J. S. (2005). Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science, 310(5753), 1504–1510.PubMedCrossRef
36.
Hull, M. A., Ko, S. C., & Hawcroft, G. (2004). Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Molecular Cancer Therapeutics, 3(8), 1031–1039.PubMed
37.
Backlund, M. G., Mann, J. R., & Dubois, R. N. (2005). Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology, 69(Suppl 1), 28–32.PubMedCrossRef
38.
Wang, D., Wang, H., Brown, J., Daikoku, T., Ning, W., Shi, Q., et al. (2006). CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. The Journal of Experimental Medicine, 203(4), 941–951.PubMedPubMedCentralCrossRef
39.
Majumder, M., Xin, X., Liu, L., Tutunea-Fatan, E., Rodriguez-Torres, M., Vincent, K., et al. (2016). COX-2 induces breast cancer stem cells via EP4/PI3K/AKT/NOTCH/WNT Axis. Stem Cells, 34(9), 2290–2305.PubMedCrossRef
40.
Du, M., Shi, F., Zhang, H., Xia, S., Zhang, M., Ma, J., et al. (2015). Prostaglandin E2 promotes human cholangiocarcinoma cell proliferation, migration and invasion through the upregulation of beta-catenin expression via EP3-4 receptor. Oncology Reports, 34(2), 715–726.PubMedCrossRef
41.
Vaid, M., Singh, T., Prasad, R., Kappes, J. C., & Katiyar, S. K. (2015). Therapeutic intervention of proanthocyanidins on the migration capacity of melanoma cells is mediated through PGE2 receptors and beta-catenin signaling molecules. American Journal of Cancer Research, 5(11), 3325–3338.PubMedPubMedCentral
42.
Auersperg, N. (2011). The origin of ovarian carcinomas: a unifying hypothesis. International Journal of Gynecological Pathology: Official Journal of the International Society of Gynecological Pathologists, 30(1), 12–21.CrossRef
43.
Kim, J., Coffey, D. M., Creighton, C. J., Yu, Z., Hawkins, S. M., & Matzuk, M. M. (2012). High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proceedings of the National Academy of Sciences of the United States of America, 109(10), 3921–3926.PubMedPubMedCentralCrossRef
44.
Kurman, R. J., & Shih Ie, M. (2010). The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. The American Journal of Surgical Pathology, 34(3), 433–443.PubMedPubMedCentralCrossRef
45.
46.
Lee, Y., Miron, A., Drapkin, R., Nucci, M. R., Medeiros, F., Saleemuddin, A., et al. (2007). A candidate precursor to serous carcinoma that originates in the distal fallopian tube. The Journal of Pathology, 211(1), 26–35.PubMedCrossRef
47.
Shih Ie, M., & Kurman, R. J. (2004). Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. The American Journal of Pathology, 164(5), 1511–1518.PubMedCrossRef
48.
Auersperg, N., Edelson, M. I., Mok, S. C., Johnson, S. W., & Hamilton, T. C. (1998). The biology of ovarian cancer. Seminars in Oncology, 25(3), 281–304.PubMed
49.
50.
Mills, G. B., May, C., Hill, M., Campbell, S., Shaw, P., & Marks, A. (1990). Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. The Journal of Clinical Investigation, 86(3), 851–855.PubMedPubMedCentralCrossRef
51.
Xu, Y., Gaudette, D. C., Boynton, J. D., Frankel, A., Fang, X. J., Sharma, A., et al. (1995). Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 1(10), 1223–1232.
52.
Xu, Y., Shen, Z., Wiper, D. W., Wu, M., Morton, R. E., Elson, P., et al. (1998). Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA, 280(8), 719–723.PubMedCrossRef
53.
Hecht, J. H., Weiner, J. A., Post, S. R., & Chun, J. (1996). Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. The Journal of Cell Biology, 135(4), 1071–1083.PubMedCrossRef
54.
Yang, M., Zhong, W. W., Srivastava, N., Slavin, A., Yang, J., Hoey, T., et al. (2005). G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the beta-catenin pathway. Proceedings of the National Academy of Sciences of the United States of America, 102(17), 6027–6032.PubMedPubMedCentralCrossRef
55.
56.
Ranjan, R., Dwivedi, H., Baidya, M., Kumar, M., & Shukla, A. K. (2017). Novel structural insights into GPCR-beta-arrestin interaction and signaling. Trends in Cell Biology, S0962-8924(17), 30087–30089.
57.
Cahill 3rd, T. J., Thomsen, A. R., Tarrasch, J. T., Plouffe, B., Nguyen, A. H., Yang, F., et al. (2017). Distinct conformations of GPCR-beta-arrestin complexes mediate desensitization, signaling, and endocytosis. Proceedings of the National Academy of Sciences of the United States of America, 114(10), 2562–2567.PubMedPubMedCentralCrossRef
58.
Jean-Charles, P. Y., Kaur, S., & Shenoy, S. K. (2017). G protein-coupled receptor signaling through beta-arrestin-dependent mechanisms. Journal of Cardiovascular Pharmacology, 70(3), 142–158.PubMedCrossRef
59.
Hinsley, E. E., Hunt, S., Hunter, K. D., Whawell, S. A., & Lambert, D. W. (2012). Endothelin-1 stimulates motility of head and neck squamous carcinoma cells by promoting stromal-epithelial interactions. International Journal of Cancer, 130(1), 40–47.PubMedCrossRef
60.
Kim, T. H., Xiong, H., Zhang, Z., & Ren, B. (2005). Beta-catenin activates the growth factor endothelin-1 in colon cancer cells. Oncogene, 24(4), 597–604.PubMedCrossRef
61.
Rosanò, L., Cianfrocca, R., Masi, S., Spinella, F., Di Castro, V., Biroccio, A., et al. (2009). Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 106(8), 2806–2811.PubMedPubMedCentralCrossRef
62.
Rosanò, L., Cianfrocca, R., Tocci, P., Spinella, F., Di Castro, V., Spadaro, F., et al. (2013). Beta-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced beta-catenin signaling. Oncogene, 32(42), 5066–5077.PubMedCrossRef
63.
Spinella, F., Caprara, V., Di Castro, V., Rosano, L., Cianfrocca, R., Natali, P. G., et al. (2013). Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. Journal of Molecular Medicine, 91(3), 395–405.PubMedCrossRef
64.
Sun, P., Xiong, H., Kim, T. H., Ren, B., & Zhang, Z. (2006). Positive inter-regulation between beta-catenin/T cell factor-4 signaling and endothelin-1 signaling potentiates proliferation and survival of prostate cancer cells. Molecular Pharmacology, 69(2), 520–531.PubMedCrossRef
65.
de Lau, W., Barker, N., Low, T. Y., Koo, B. K., Li, V. S., Teunissen, H., et al. (2011). Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature, 476(7360), 293–297.PubMedCrossRef
66.
Carmon, K. S., Gong, X., Lin, Q., Thomas, A., & Liu, Q. (2011). R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/beta-catenin signaling. Proceedings of the National Academy of Sciences of the United States of America, 108(28), 11452–11457.PubMedPubMedCentralCrossRef
67.
Hao, H. X., Xie, Y., Zhang, Y., Charlat, O., Oster, E., Avello, M., et al. (2012). ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature, 485(7397), 195–200.PubMedCrossRef
68.
Koo, B. K., Spit, M., Jordens, I., Low, T. Y., Stange, D. E., van de Wetering, M., et al. (2012). Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature, 488(7413), 665–669.PubMedCrossRef
69.
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., et al. (2009). Crypt stem cells as the cells-of-origin of intestinal cancer. Nature, 457(7229), 608–611.PubMedCrossRef
70.
Barker, N., Tan, S., & Clevers, H. (2013). Lgr proteins in epithelial stem cell biology. Development, 140(12), 2484–2494.PubMedCrossRef
71.
Munoz, J., Stange, D. E., Schepers, A. G., van de Wetering, M., Koo, B. K., Itzkovitz, S., et al. (2012). The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent '+4' cell markers. The EMBO Journal, 31(14), 3079–3091.PubMedPubMedCentralCrossRef
72.
van der Flier, L. G., van Gijn, M. E., Hatzis, P., Kujala, P., Haegebarth, A., Stange, D. E., et al. (2009). Transcription factor achaete scute-like 2 controls intestinal stem cell fate. Cell, 136(5), 903–912.PubMedCrossRef
73.
Ramalingam, S., Daughtridge, G. W., Johnston, M. J., Gracz, A. D., & Magness, S. T. (2012). Distinct levels of Sox9 expression mark colon epithelial stem cells that form colonoids in culture. American Journal of Physiology. Gastrointestinal and Liver Physiology, 302(1), G10–G20.PubMedCrossRef
74.
Furuyama, K., Kawaguchi, Y., Akiyama, H., Horiguchi, M., Kodama, S., Kuhara, T., et al. (2011). Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nature Genetics, 43(1), 34–41.PubMedCrossRef
75.
Clevers, H. (2013). The intestinal crypt, a prototype stem cell compartment. Cell, 154(2), 274–284.PubMedCrossRef
76.
Reya, T., & Clevers, H. (2005). Wnt signalling in stem cells and cancer. Nature, 434(7035), 843–850.PubMedCrossRef
77.
Logan, C. Y., & Nusse, R. (2004). The Wnt signaling pathway in development and disease. Annual Review of Cell and Developmental Biology, 20, 781–810.PubMedCrossRef
78.
Marikawa, Y. (2006). Wnt/beta-catenin signaling and body plan formation in mouse embryos. Seminars in Cell & Developmental Biology, 17(2), 175–184.CrossRef
79.
Harland, R., & Gerhart, J. (1997). Formation and function of Spemann’s organizer. Annual Review of Cell and Developmental Biology, 13, 611–667.PubMedCrossRef
80.
Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler, K. W., et al. (1997). Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science, 275(5307), 1784–1787.PubMedCrossRef
81.
82.
Major, M. B., Roberts, B. S., Berndt, J. D., Marine, S., Anastas, J., Chung, N., et al. (2008). New regulators of Wnt/beta-catenin signaling revealed by integrative molecular screening. Science Signaling, 1(45), ra12.PubMed
83.
Regard, J. B., Cherman, N., Palmer, D., Kuznetsov, S. A., Celi, F. S., Guettier, J. M., et al. (2011). Wnt/beta-catenin signaling is differentially regulated by Galpha proteins and contributes to fibrous dysplasia. Proceedings of the National Academy of Sciences of the United States of America, 108(50), 20101–20106.PubMedPubMedCentralCrossRef
84.
Katanaev, V. L., Ponzielli, R., Semeriva, M., & Tomlinson, A. (2005). Trimeric G protein-dependent frizzled signaling in Drosophila. Cell, 120(1), 111–122.PubMedCrossRef
85.
Mo, J. S., Yu, F. X., Gong, R., Brown, J. H., & Guan, K. L. (2012). Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). Genes & Development, 26(19), 2138–2143.CrossRef
86.
87.
Slusarski, D. C., Corces, V. G., & Moon, R. T. (1997). Interaction of Wnt and a Frizzled homologue triggers G-protein-linked phosphatidylinositol signalling. Nature, 390(6658), 410–413.PubMedCrossRef
88.
Feng, X., Degese, M. S., Iglesias-Bartolome, R., Vaque, J. P., Molinolo, A. A., Rodrigues, M., et al. (2014). Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell, 25(6), 831–845.PubMedPubMedCentralCrossRef
89.
Park, H. W., Kim, Y. C., Yu, B., Moroishi, T., Mo, J. S., Plouffe, S. W., et al. (2015). Alternative Wnt signaling activates YAP/TAZ. Cell, 162(4), 780–794.PubMedPubMedCentralCrossRef
90.
Meng, Z., Moroishi, T., & Guan, K. L. (2016). Mechanisms of Hippo pathway regulation. Genes & Development, 30(1), 1–17.CrossRef
91.
Yu, F. X., Zhao, B., Panupinthu, N., Jewell, J. L., Lian, I., Wang, L. H., et al. (2012). Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell, 150(4), 780–791.PubMedPubMedCentralCrossRef
92.
Burger, M. M. (1970). Proteolytic enzymes initiating cell division and escape from contact inhibition of growth. Nature, 227(5254), 170–171.PubMedCrossRef
93.
Carney, D. H., & Cunningham, D. D. (1977). Initiation of check cell division by trypsin action at the cell surface. Nature, 268(5621), 602–606.PubMedCrossRef
94.
Chen, L. B., & Buchanan, J. M. (1975). Mitogenic activity of blood components. I. Thrombin and prothrombin. Proceedings of the National Academy of Sciences of the United States of America, 72(1), 131–135.PubMedPubMedCentralCrossRef
95.
Rasmussen, U. B., Vouret-Craviari, V., Jallat, S., Schlesinger, Y., Pages, G., Pavirani, A., et al. (1991). cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ mobilization. FEBS Letters, 288(1–2), 123–128.PubMedCrossRef
96.
Vu, T. K., Hung, D. T., Wheaton, V. I., & Coughlin, S. R. (1991). Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell, 64(6), 1057–1068.PubMedCrossRef
97.
Coughlin, S. R. (1994). Protease-activated receptors start a family. Proceedings of the National Academy of Sciences of the United States of America, 91(20), 9200–9202.PubMedPubMedCentralCrossRef
98.
Nystedt, S., Emilsson, K., Wahlestedt, C., & Sundelin, J. (1994). Molecular cloning of a potential proteinase activated receptor. Proceedings of the National Academy of Sciences of the United States of America, 91(20), 9208–9212.PubMedPubMedCentralCrossRef
99.
O'Brien, P. J., Prevost, N., Molino, M., Hollinger, M. K., Woolkalis, M. J., Woulfe, D. S., et al. (2000). Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. The Journal of Biological Chemistry, 275(18), 13502–13509.PubMedCrossRef
100.
Jaber, M., Maoz, M., Kancharla, A., Agranovich, D., Peretz, T., Grisaru-Granovsky, S., et al. (2014). Protease-activated-receptor-2 affects protease-activated-receptor-1-driven breast cancer. Cellular and Molecular Life Sciences: CMLS, 71(13), 2517–2533.PubMedCrossRef
101.
Sevigny, L. M., Austin, K. M., Zhang, P., Kasuda, S., Koukos, G., Sharifi, S., et al. (2011). Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia. Arteriosclerosis, Thrombosis, and Vascular Biology, 31(12), e100–e106.PubMedPubMedCentralCrossRef
102.
McLaughlin, J. N., Patterson, M. M., & Malik, A. B. (2007). Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proceedings of the National Academy of Sciences of the United States of America, 104(13), 5662–5667.PubMedPubMedCentralCrossRef
103.
Leger, A. J., Jacques, S. L., Badar, J., Kaneider, N. C., Derian, C. K., Andrade-Gordon, P., et al. (2006). Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation, 113(9), 1244–1254.PubMedCrossRef
104.
Blackhart, B. D., Emilsson, K., Nguyen, D., Teng, W., Martelli, A. J., Nystedt, S., et al. (1996). Ligand cross-reactivity within the protease-activated receptor family. The Journal of Biological Chemistry, 271(28), 16466–16471.PubMedCrossRef
105.
Ishihara, H., Connolly, A. J., Zeng, D., Kahn, M. L., Zheng, Y. W., Timmons, C., et al. (1997). Protease-activated receptor 3 is a second thrombin receptor in humans. Nature, 386(6624), 502–506.PubMedCrossRef
106.
Kahn, M. L., Zheng, Y. W., Huang, W., Bigornia, V., Zeng, D., Moff, S., et al. (1998). A dual thrombin receptor system for platelet activation. Nature, 394(6694), 690–694.PubMedCrossRef
107.
Xu, W. F., Andersen, H., Whitmore, T. E., Presnell, S. R., Yee, D. P., Ching, A., et al. (1998). Cloning and characterization of human protease-activated receptor 4. Proceedings of the National Academy of Sciences of the United States of America, 95(12), 6642–6646.PubMedPubMedCentralCrossRef
108.
Even-Ram, S., Uziely, B., Cohen, P., Grisaru-Granovsky, S., Maoz, M., Ginzburg, Y., et al. (1998). Thrombin receptor overexpression in malignant and physiological invasion processes. Nature Medicine, 4(8), 909–914.PubMedCrossRef
109.
Nag, J. K., Kancharla, A., Maoz, M., Turm, H., Agranovich, D., Gupta, C. L., et al. (2017). Low-density lipoprotein receptor-related protein 6 is a novel coreceptor of protease-activated receptor-2 in the dynamics of cancer-associated beta-catenin stabilization. Oncotarget, 8(24), 38650–38667.PubMedPubMedCentralCrossRef
110.
Kancharla, A., Maoz, M., Jaber, M., Agranovich, D., Peretz, T., Grisaru-Granovsky, S., et al. (2015). PH motifs in PAR1&2 endow breast cancer growth. Nature Communications, 6, 8853–8865.PubMedPubMedCentralCrossRef
111.
Yin, Y. J., Katz, V., Salah, Z., Maoz, M., Cohen, I., Uziely, B., et al. (2006). Mammary gland tissue targeted overexpression of human protease-activated receptor 1 reveals a novel link to beta-catenin stabilization. Cancer Research, 66(10), 5224–5233.PubMedCrossRef
Metadaten
Titel
Cancer driver G-protein coupled receptor (GPCR) induced β-catenin nuclear localization: the transcriptional junction
verfasst von
Jeetendra Kumar Nag
Tatyana Rudina
Myriam Maoz
Sorina Grisaru-Granovsky
Beatrice Uziely
Rachel Bar-Shavit
Publikationsdatum
08.12.2017
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 1/2018
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-017-9711-z

Weitere Artikel der Ausgabe 1/2018

Cancer and Metastasis Reviews 1/2018 Zur Ausgabe

OriginalPaper

Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy

OriginalPaper

MiR-181 family-specific behavior in different cancers: a meta-analysis view

Announcement

Biographies

Correction

Correction to: Cancer driver G-protein coupled receptor (GPCR) induced β-catenin nuclear localization: the transcriptional junction

OriginalPaper

MicroRNAs and metastasis: small RNAs play big roles

CLINICAL

Current perspectives on bone metastases in castrate-resistant prostate cancer

Neu im Fachgebiet Onkologie

17.04.2024 | Mammakarzinom | Nachrichten

Adjuvante Brustkrebstherapie: Doppelt hält besser

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Manche Gestagene können das Risiko für Meningeome erhöhen

10.04.2024 | PSA-Screening | Nachrichten

Einladung zum PSA-Screening senkt die Krebssterblichkeit

09.04.2024 | DGP 2024 | Kongressbericht | Nachrichten

Chemotherapie mit Hindernissen
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen